Investigational drug · Phase 2
Kylo 0603
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metabolic Dysfunction-Associated Steatoic Liver Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Kylo 0603"
First trial start
2026
Nov 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Kylo 0603", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metabolic Dysfunction-Associated Steatoic Liver Disease
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Kylo 0603" as an intervention, largest first.
- A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)Pivotal-lookingNot yet recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07878091 · 120 participants (planned) · Start Nov 15, 2026 · Primary completion Aug 15, 2027
Drug: Kylo 0603 Capsule 8mg; Kylo 0603 Capsule 12mg and 2 more · For: Metabolic Dysfunction-Associated Steatoic Liver Disease
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression.
Lu X, Wang S, Du Y, et al. · PLoS One 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.